Ashley Gallagher, Editor

The results showed that one 300 mg dose of AZD7442 reduced the risk of developing symptomatic COVID-19 by 83% and one 600 mg dose reduced the risk of developing severe COVID-19 or death (from any cause) by 88% compared to the placebo.

Investigators have developed an encapsulated and immobilized individual bacterium cell in crystalline polymeric matric that not only kills the bacterium but preserves and stabilizes the dead cell against high temperature, moisture, and organic solvents. The method utilizes metal-organic frameworks (MOFs).

Survey results show 81% think the psychoactive drug will play a role in chronic pain management.

Almost 80% of individuals with type 2 diabetes lost more than 22 pounds and maintained that weight loss in remission for at least 2 years, study results show.

Herpes zoster ophthalmicus develops when a varicella-zoster virus infection is reactivated, generally in those who are immunocompromised, and leads to chronic ocular complications.

The analysis found that vaccination rates increased from 36% to 60% between January 2021 and April 2021 but then slowed, reaching just 70% as of September 2021.

Under the agreement, the government would acquire 10 million treatment courses to be delivered by Pfizer beginning later this year and concluding in 2022.

Individuals treated with Wegovy who are obese are overweight are more likely to lose at least 5% of their body weight compared with the placebo.

Investigators from Michigan Medicine analyzed data from 16,700 individuals in a new study.

However, many say that they would reconsider if local COVID-19 cases begin to spike at their destination, poll results show.

Investigators have developed an immunotherapy that is a potential option for children with hard-to-treat brain cancer.

Investigators used mouse models and found that the stress hormone suppressed the innate immune system that normally protects the gut from bacteria that is associated with the condition.

The Pfizer COVID-19 vaccine booster dose is the same strength as the primary series of the Pfizer COVID-19 vaccine, with findings demonstrating the same level of safety as the primary series.

Those with attention-deficit/hyperactivity disorder are much more likely to have GAD at some point in their lives than others who do not have it.

Breast cancer found to be the most expensive type of the disease, costing approximately $3.4 billion in the United States.

The Build Back Better bill include an authorization for the government to negotiate lower drug prices.

The guidance updates the recommendations on dopaminergic medications that were published in 2002 on the initiation treatment for Parkinson disease.

Their statement also calls upon the business community to support the new federal requirement that individuals working for companies with more than 100 employees be vaccinated.

The results of a study showed that non-Hispanic Black patients treated with immunotherapy had a 15% lower risk of death from non–small cell lung cancer than non-Hispanic white patients.

After 6 to 7 months, just 8 individuals contracted proven symptomatic SARS-CoV-2 infection with rapid favorable evolution, study results show.

Results of studies show about 61% of individuals with PV experienced a complete hematological response.

Clinical trial findings show that the 2-year overall survival rate for those who received this was 72%.

Atrial fibrillation was more common in those not treated with radiation (66.5%) or surgery (23.5%) as first-line treatment compared with 52.3% and 10.4%, respectively.

Study results show that the type of vaccine patients received was a major factor in inducing an immune response, with those receiving mRNA shots faring better.

If approved, empagliflozin would be the first therapy proven to significantly improve outcomes for individuals with heart failure, according to Boehringer Ingelheim.

They are attempting to determine the associations and connections to further benefit individuals using the therapies.

Study results show no differences in the rate of neuropathic pain, surgical site infection, wound-related complications, or other complications between the 2 groups.

After adjusting for age, education level, and gender, each 1-point increase in dietary inflammatory score was linked to a 21% increase in cognitive impairment, study results show.

PRISM-EXT shows data consistent with those of PRISM3, which provided significant improvement compared with the placebo through 8 weeks and 24 weeks post-treatment.

The report also describes the benefits of interventions at the family, individual, institutional, organizational, and policy levels and differentiates AD from other types of dementia.